The abstract is read at the publisher; the summary is JClub's.
In specialist-treated obesity-associated moderate-to-severe asthma without diabetes, tirzepatide initiation is linked to a lower hazard of severe exacerbation than tezepelumab (wHR 0.41; 95% CI 0.24–0.70).
- Why it matters: Obesity is associated with worse asthma outcomes, and existing biologics may not address weight-related airway inflammation pathways.
- What they did: In a multi-institutional EHR cohort (2779 patients) from 2022–2025, researchers compared liraglutide, semaglutide, tirzepatide, and tezepelumab using overlap weighting and follow-up for exacerbations, rescue inhalers, respiratory encounters, and time to >10% BMI loss.
- The result: Weighted estimates showed semaglutide had a similar severe-exacerbation hazard to tezepelumab (wHR 0.99; 95% CI 0.70–1.39), while tirzepatide and semaglutide reached >10% BMI reduction sooner and had fewer rescue inhaler needs and respiratory-related encounters than tezepelumab.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.